ArticleHeliyon2025
Characterization of the immune cell infiltration patterns in lung adenocarcinoma to facilitate immunotherapy.
Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Global research trends and focus on biomarkers in lung cancer immunotherapy: a comprehensive bibliometric insight and visualization analysis (2001-2025).Frontiers in immunology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although Immunotherapy has emerged as an efficient treatment in lung carcinoma, merely a subset of lung adenocarcinoma (LUAD) patients could be benefited from it. Increasing evidence revealed that tumor immune cell infiltrating (ICI) in the tumor microenvironment (TME) is highly related to patient prognosis and characteristics of the tumor. Thus far, the immune cell infiltration patterns of LUAD remain unclear. Herein, ESTIMATE and CIBERSORT algorithms were conducted to characterize the ICI patterns of 1155 patients with LUAD. Three ICI subtypes were determined, and the ICI score was constructed by performing PCA. A high ICI score group referred to increased activation of the signaling pathways related to immune activation and drug metabolism, reduced tumor mutation burden (TMB), as well as significantly higher expression levels of CTLA-4, PD-1, LAG3, and immune-activation-related genes. Patients who had high ICI scores showed better overall survival (OS) compared to those with low ICI scores, irrespective of TMB status. This study demonstrated that ICI scores serve as an original and effective indicator for independent prognostic prediction as well as customized immune therapy of LUAD. Establishing the ICI patterns of a larger patient population will extend our knowledg of TME, and it may facilitate the development of immunotherapies specific to LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.